A phase 2 study suggests that immunotherapy plus radiation could spare some patients with advanced endometrial cancer from chemotherapy.

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

In this study, researchers aimed to identify endometrial cancer patient preferences and gather insights on how these preferences might inform treatment decisions.

—A study that explored trends in obesity and endometrial cancer in the U.S concluded that the combination of the 2 conditions hits younger women, and Black and Hispanic women in particular, the ...

—A new study from California-based researchers reports that things may be getting worse for certain women at risk for endometrial cancer. Here’s what the research team adds to what’s known about ...

In January, the American Cancer Society reported that for the first time women younger than 50 had a higher cancer incidence rate than men. Based on 2023 data, cancer incidence rates among women under ...

Taking at least 30 ibuprofen pills per month was associated with a significant reduction in the risk of endometrial cancer when compared to taking fewer than 4 pills per month. Frequent use of ...

A combination of Verzenio and letrozole has shown encouraging and lasting responses in patients with advanced or recurrent ...

Data from the SISTER study show that 1:1 peer support significantly increases the odds that Black women with endometrial cancer will complete treatment, according to research pres ...